5 Popular Penny Stocks on Robinhood to Watch in 2026

3. Quince Therapeutics, Inc. (NASDAQ:QNCX)

Stock Price as of Last Close of May 26: $1.20

Quine Therapeutics, Inc. (NASDAQ:QNCX) is among the most popular penny stocks. 

TheFly reported that QNCX presented Phase 2a clinical results for LAM-001 on May 18, at the American Thoracic Society conference in Orlando, evaluating an inhaled rapamycin formulation for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The drug was studied as an add-on to standard therapy in a 24-week, open-label trial across four sites involving 10 symptomatic adult patients. Outcomes assessed included exercise capacity, pulmonary hemodynamics, cardiac biomarkers, and safety measures.

Results showed improvements or stabilization across multiple disease indicators such as six-minute walk distance, pulmonary vascular resistance, NT-proBNP levels, and lung function metrics. Most patients improved functional class status over the study period, and the treatment was generally well tolerated alongside background therapies, including treprostinil in PH-ILD patients.

Simultaneously, on the same day, Quine Therapeutics, Inc. (NASDAQ:QNCX) announced the completion of its acquisition of Orphai Therapeutics Inc. on May 18, 2026, integrating Orphai’s lead candidate LAM-001 into its pipeline for rare pulmonary diseases. LAM-001, an inhaled rapamycin formulation, has recently shown Phase 2 clinical results in pulmonary arterial hypertension and PH-ILD. Alongside the acquisition, the company entered a financing arrangement expected to raise to $187 million in gross proceeds, including initial and potential additional warrant-based funding.

The capital is intended to support the advancement of LAM-001 through multiple upcoming clinical milestones across pulmonary indications, including PH-ILD, BOS, and sarcoidosis-associated pulmonary hypertension. Management highlighted that the transaction strengthens both the company’s pipeline and financial position.

Quine Therapeutics, Inc. (NASDAQ:QNCX) is a biotech company developing rare disease therapies using patients’ own biology. In May 2026, it expanded its pipeline by acquiring Orphai Therapeutics, adding programs in rare pulmonary and cardiovascular diseases.